Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas

Trial Profile

Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
    • 16 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
    • 17 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top